Day Two
7:50 am Coffee & Registration
8:50 am Opening Remarks
Mapping Insights with Digital Pathology & Spatial Biology to Accelerate Drug Discovery
9:00 am Leveraging Digital Pathology & AI Analytics to Drive Novel Insights into Disease Pathophysiology
Synopsis
- Utilising digital pathology and advanced analytics to enable deeper understanding of the complexity and underlying mechanisms of the tumour microenvironment
- Employing AI to analyse protein expression and decipher complex pathophysiology
9:30 am Roundtable: Leveraging the Power of CRISPR for the Development of Cutting-Edge Models
Synopsis
- Rapidly creating complex organoid cultures and animal models
- Engineering multiple in vivo mouse models in parallel and deriving combinations of genetic alterations
10:00 am Interrogating AI-Based Approaches & Digital Pathology to Elucidate Biomarker Expression & Drug Response
Synopsis
- Applying deep-learning algorithms to recognise and quantify image features associated with clinically important outcomes
- Investigating retrospective and prospective uses of AI and digital pathology to extract biomarkers from histology images
10:30 am Morning Break & Networking
Unlocking Forward & Reverse Translational Studies to Revolutionise Precision Medicine
11:30 am Addressing Project Optimus: Use of Preclinical, Modelling, & Clinical Data to Identify the Optimal Dose of the PARP1-Selective Agent Saruparib for Phase 3 Studies
Synopsis
- Interrogating in vitro models to understand mechanisms of action and exposure thresholds for activity
- Analysing in vivo models to understand dose responses and exposure relationships needed for optimal efficacy
- Exploring mathematical quantitative systems pharmacology modeling to correlation of clinical exposures, PD and efficacy in relation to preclinical data and modeling
- Understanding how cross-validation of preclinical results with patient outcomes can drive more effective and personalised cancer treatments
12:00 pm Bedside to Bench: Interrogating Preclinical Models for Precision Oncology
Synopsis
- Exploring how precision oncology customises cancer treatment based on the genetic and molecular profiles of patients’ tumours
- Utilising mono- and co-culture patient-derived organoids (PDOs) and xenografts to help identify biomarkers for optimising regorafenib treatment in metastatic colorectal cancer
- Using paired tissue and liquid biopsies from a phase II trial, identified MIR652-3p as a biomarker and molecular driver of resistance to regorafenib
Evaluating In Vitro & Complex 3D Models for Precinical Research
12:30 pm Elucidating the Value of 3D Models in Preclinical Drug Discovery, Target Validation, & Safety Assessment
Synopsis
- Analysing the pros and cons of utilising 3D models in the development of personalised medicines
- Investigating the potential of 3D models to confidently validate drug targets and conduct comprehensive preclinical safety assessments
- Examining how regulatory bodies perceive the use of 3D models in preclinical packages and their integration into regulatory submissions for IND/CTA approvals
1:00 pm Lunch & Netowrking
2:00 pm Characterization of Physiologically Relevant Ex Vivo Models
Synopsis
- Understanding pros and cons of working with patient-derived 3D tumour models
- Development of functional readouts pertinent to the selected models
- Assessment of ex vivo efficacy to immune modulators
2:30 pm 3D Bioprinted Bone Mimics for Cancer Research & Drug Screening
Synopsis
- Discussing the development of these models
- Interrogating how these models can be used to study metastases and for drug screening
Model Validation & Characterisation to Optimise Research Efficiency & Increase Translational Impact
3:00 pm Comparative Study to Validate Genomics Vendors
Synopsis
- Evaluating the efficacy of each technique to determine the optimal workflow
- Comparing the analysis of protein and RNA on the same slide versus separate slides to identify the best service providers
3:30 pm Afternoon Break & Networking
4:00 pm Panel: Optimising Preclinical Research: Comparing Organoids, GEMMS, PDX, & Cell-Lines
Synopsis
- Highlighting the key attributes of each model in the context of their specific research questions
- Analysing the cost and time implications of working with each type of models and how this should be taken into account when picking the right model
Uncovering Regulatory Insights for Successful Drug Development
4:30 pm Exploring Regulatory Ingredients in Pharmaceutical Development for Oncology Medicine
Synopsis
- Highlighting AI concepts and use in precision medicine
- Identifying biomarker concepts today and outlook
- Examining general pharmaceutical legislations in Europe and HTAR